Stockreport

Icosavax Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Icosavax, Inc.  (ICVX) 
PDF - Initiated a Phase 1/2 clinical trial for IVX-411, a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain - - Initiated a Phase 1/1b clinica [Read more]